All Outputs (10)

Provider‐related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis (2020)
Journal Article
Whiteley, D., Speakman, E., Elliott, L., Davidson, K., Hamilton, E., Jarvis, H., …Flowers, P. (2021). Provider‐related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis. Journal of Viral Hepatitis, 28(3), 528-537. https://doi.org/10.1111/jvh.13443

The ease of Direct Acting Antiviral (DAA) medications for hepatitis C virus (HCV) has provided an opportunity to decentralise HCV treatment into community settings. However, the role of non-specialist clinicians in community-based pathways has recei... Read More about Provider‐related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol) (2019)
Journal Article
Hickman, M., Dillon, J. F., Elliott, L., De Angelis, D., Vickerman, P., Foster, G., …Hutchinson, S. J. (2019). Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). BMJ Open, 9(9), Article e029538. https://doi.org/10.1136/bmjopen-2019-029538

Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting drug use as the main risk factor among the estimated 200 000 people currently infected. Despite effective prevention interventions, chronic HCV preva... Read More about Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol).

Hepatitis C in a new therapeutic era: Recontextualising the lived experience (2017)
Journal Article
Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2017). Hepatitis C in a new therapeutic era: Recontextualising the lived experience. Journal of Clinical Nursing, https://doi.org/10.1111/jocn.14083

Aims and Objectives To explore the experience of adults living with hepatitis C in a new era of interferon-free treatment. Background Hepatitis C is a leading cause of morbidity and mortality worldwide, posing a significant challenge to global pub... Read More about Hepatitis C in a new therapeutic era: Recontextualising the lived experience.

The Lived Experience of Interferon-free Treatments for Hepatitis C: A Thematic Analysis (2017)
Presentation / Conference
Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2017, March). The Lived Experience of Interferon-free Treatments for Hepatitis C: A Thematic Analysis. Poster presented at NHS Lothian R&D Conference 2017

no abstract available.

Recontextualising the lived experience of hepatitis C and its treatment (2016)
Thesis
Whiteley, D. J. (2016). Recontextualising the lived experience of hepatitis C and its treatment. (Thesis). Edinburgh Napier University. Retrieved from http://researchrepository.napier.ac.uk/Output/979740

BACKGROUND: Rapid advances in the treatment of the hepatitis C virus (HCV) have been witnessed in clinical practice over the last five years. Pharmacological developments have ended the reliance on the drug interferon-α as a component of successful t... Read More about Recontextualising the lived experience of hepatitis C and its treatment.

The lived experience of interferon-free treatments for hepatitis C: A thematic analysis (2016)
Journal Article
Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2016). The lived experience of interferon-free treatments for hepatitis C: A thematic analysis. International Journal of Drug Policy, 38, 21-28. https://doi.org/10.1016/j.drugpo.2016.10.013

Background: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduced side-effects of interferon-free regimens. How these treatments are being... Read More about The lived experience of interferon-free treatments for hepatitis C: A thematic analysis.

Qualitative insights into the lived experience of interferon-free treatments (2016)
Presentation / Conference
Whiteley, D. (2016, September). Qualitative insights into the lived experience of interferon-free treatments. Paper presented at 5th International Symposium on Hepatitis Care in Substance Users

BACKGROUND: Previous research has focused on the experience of individuals undergoing interferon (IFN) based treatment for hepatitis C (HCV), however qualitative insights into the experience of IFN-free therapy are currently absent from the scientifi... Read More about Qualitative insights into the lived experience of interferon-free treatments.

Health-Related Quality of Life for individuals with hepatitis C: A narrative review (2015)
Journal Article
Whiteley, D., Elliott, L., Cunningham-Burley, S., & Whittaker, A. (2015). Health-Related Quality of Life for individuals with hepatitis C: A narrative review. International Journal of Drug Policy, 26(10), 936-949. https://doi.org/10.1016/j.drugpo.2015.04.019

BACKGROUND The assessment of Health-Related Quality of Life (HRQoL) in hepatitis C (HCV) infected individuals continues to gain importance. However, rarely do reviews of this literature consider quantitative and qualitative accounts of HRQoL colle... Read More about Health-Related Quality of Life for individuals with hepatitis C: A narrative review.

Why aren't we treating the treatable? An audit of all HIV/HCV co-infected individuals attending an HIV clinic (2011)
Presentation / Conference
Whiteley, D. (2011, April). Why aren't we treating the treatable? An audit of all HIV/HCV co-infected individuals attending an HIV clinic. Poster presented at 17th Annual Conference of the British HIV Association (BHIVA)

Poster abstracts.

Audit of eligibility of hepatitis C/HIV co-infected patients in the Lothian Regional Infectious Diseases Unit cohort for new HCV protease inhibitor containing regimens
Presentation / Conference
Devine, K., Whiteley, D., & Leen, C. Audit of eligibility of hepatitis C/HIV co-infected patients in the Lothian Regional Infectious Diseases Unit cohort for new HCV protease inhibitor containing regimens

Background: Introduction of the new HCV protease inhibitors has been shownto improve outcomes for mono-infected patients. Recent data showssignificant decline in HCV RNA at 24 weeks in genotype 1 co-infectedpatients on HAART who received either Telap... Read More about Audit of eligibility of hepatitis C/HIV co-infected patients in the Lothian Regional Infectious Diseases Unit cohort for new HCV protease inhibitor containing regimens.